FDA holds social media guidance webinar

Technology is continually changing, but FDA’s commitment to public health does not. In today’s world, a tremendous amount of information exchange occurs on the web and through social media.  In 2014, FDA’s Office of Prescription Drug Promotion released three highly-anticipated draft guidances detailing FDA’s current views and recommendations on specific social media topics.


OPDP, in the Center for Drug Evaluation and Research (CDER) consulted with other FDA Centers, including the Center for Biologics Evaluation and Research (CBER), the Center for Veterinary Medicine (CVM), and the Center for Devices and Radiological Health (CDRH).


To further our communications with stakeholders, media and the public in this area, FDA will host a webinar and Q&A session on July 10, 2014, from 2:00-3:00 p.m. (EST).


The purpose of this webinar is to provide an introduction and overview of FDA’s three recently issued social media draft guidances Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and BiologicsInternet/Social Media Platforms with Character Space Limitations— Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices and Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices.


Subject-matter experts will also be available to answer questions regarding the draft guidances and provide further explanation of key concepts.


Additional information is located at: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm397791.htm   


To register for this event, please go the following link: http://go.usa.gov/XxMJ

(Registration password needs to be 8 characters and alphanumeric)


Note: Your registration acknowledgement will include the webinar access link. Registration is limited, so please register now.


Audio will broadcast from your computer speakers.

Closed captioning will be provided.


Questions/Comments can be submitted live via a Q/A chat window.

To access the public docket or leave comments regarding the draft guidances, please visit:

This email was sent to kostikblog@ukr.net using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 Powered by GovDelivery